Aprozen Pharma
Cambridge, United States· Est.
Custom chemistry CRO delivering high‑quality API impurities, isotopes, and specialty building blocks for drug development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Custom chemistry CRO delivering high‑quality API impurities, isotopes, and specialty building blocks for drug development.
Small MoleculeMedicinal Chemistry
Technology Platform
Proprietary synthetic organic chemistry combined with isotope‑labeling and chiral synthesis capabilities to produce API impurities, metabolites, and specialty building blocks.
Opportunities
Growing demand for impurity standards and isotopically labeled compounds in regulatory submissions and ADME studies offers scalable revenue streams.
Risk Factors
Competition from larger CROs and supply‑chain volatility for specialized reagents could pressure margins and growth.
Competitive Landscape
AproZen differentiates through niche expertise in chiral and isotopically labeled syntheses, competing primarily with specialized chemical manufacturers rather than broad‑scope CROs.